4//SEC Filing
Sarepta Therapeutics, Inc. 4
Accession 0001209191-16-104941
$SRPTCIK 0000873303operating
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 9:24 PM ET
Size
16.3 KB
Accession
0001209191-16-104941
Insider Transaction Report
Form 4
Aphale Jayant
SVP Technical Operations
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2016-02-29+10,625→ 10,625 totalExercise: $13.71Exp: 2026-02-28→ Common Stock (10,625 underlying) - Award
Non-Qualified Stock Option (right to buy)
2016-02-29+14,754→ 14,754 totalExercise: $13.71Exp: 2026-02-28→ Common Stock (14,754 underlying) - Award
Incentive Stock Option (right to buy)
2016-02-29+4,375→ 4,375 totalExercise: $13.71Exp: 2026-02-28→ Common Stock (4,375 underlying) - Award
Incentive Stock Option (right to buy)
2016-02-29+246→ 246 totalExercise: $13.71Exp: 2026-02-28→ Common Stock (246 underlying) - Award
Common Stock
2016-02-29+2,352→ 12,255 total
Holdings
- 500(indirect: By Spouse)
Common Stock
Footnotes (5)
- [F1]100% of the Restricted Stock Award granted on February 29, 2016 vests six months from the date of grant. This award is being provided in lieu of a portion of the executive's cash bonus and is subject to continued service with the Issuer.
- [F2]Includes shares acquired under the Sarepta Therapeutics, Inc. 2013 Employee Stock Purchase Plan, 800 shares were acquired on February 29, 2016 at a price of $11.4665.
- [F3]Represents shares held by spouse, which were not previously reported and were acquired by the spouse of the reporting person before the reporting person became a Section 16 officer of the issuer.
- [F4]25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.
- [F5]Half of the options begin vesting in the event the FDA provides marketing approval for eteplirsen as of the applicable PDUFA date and the other half of the options begin vesting in the event Sarepta files a Marketing Authorization Application with the EMEA prior to December 31, 2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vests immediately upon achievement of the performance condition (25% of the total Performance-Based Options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total Performance-Based Options granted) vests over four years with 25% of these remaining options vesting on the first year anniversary of the grant date and 1/48th of these remaining options vesting monthly thereafter.
Documents
Issuer
Sarepta Therapeutics, Inc.
CIK 0000873303
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000873303
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 9:24 PM ET
- Size
- 16.3 KB